Searchable abstracts of presentations at key conferences in endocrinology

ea0063oc13.3 | Anterior and Posterior pituitary 2 | ECE2019

Pituitary tumour-derived chemokines modulate immune cell infiltrates in the tumour microenvironment leading to aggressive phenotype

Marques Pedro , Barry Sayka , Carlsen Eivind , Collier David , Ronaldson Amy , Awad Sherine , Mendoza Nigel , Dorward Neil , Grieve Joan , Balkwill Frances , Korbonits Marta

Introduction: Tumour microenvironment (TME) is determined by non-tumoral cells, including immune, stromal or endothelial cells, and influences tumorigenesis, proliferation, invasiveness and angiogenesis. Little is known about TME in pituitary adenomas (PAs). We aimed to characterise the TME of PAs and its role in their aggressiveness, focusing on PA-infiltrating immune cells and cytokine network.Methods: Cytokine secretome from 24 human PAs (16NFPAs, 8GH...

ea0063p236 | Pituitary and Neuroendocrinology 1 | ECE2019

Serum aryl hydrocarbon receptor-interacting protein (AIP) levels are independent of serum GH levels both at baseline and in dynamic tests of GH stimulation and suppression

Stojanovic Marko , Wu Zida , Stiles Craig , Miljic Dragana , Soldatovic Ivan , Pekic Sandra , Doknic Mirjana , Petakov Milan , Popovic Vera , Strasburger Christian , Korbonits Marta

Background and aim: Aryl hydrocarbon receptor-interacting protein (AIP) is evolutionary conserved and widely distributed throughout organism. Broad interest for AIP comes from involvement of loss-of-function AIP mutations in pituitary adenoma pathogenesis. The role of AIP in normal pituitary function is largely unknown. AIP is co-localized with GH in somatotroph secretory vesicles. Serum AIP protein was proteomically identified. We aimed at investigating whether AIP and GH are...

ea0049ep954 | Pituitary - Clinical | ECE2017

Changes in pituitary tumour biology and behaviour in FIPA patient with GH secreting aggressive pituitary macro adenoma

Miljic Dragana , Pekic Sandra , Doknic Mirjana , Nikolic-Djurovic Marina , Stojanovic Marko , Manojlovic-Gacic Emilija , Korbonits Marta , Trouillas Jaqueline , Vasiljevic Alexandre , Popovic Vera , Petakov Milan

40-year-old female patient presented with acromegaly in 2008 (GH 61 (g/L, IGF-1 774 ng/ml PRL 1500 mU/L). Macro-adenoma invading the right cavernous sinus was found on MRI and she underwent two pituitary surgeries revealing sparsely granulated GH adenoma with scattered PRL cells, low Ki 67 and negative p53 immuno-staining. Her second cousin was treated for macro prolactinoma. Both patients tested negative for germline mutations in the AIP and menin genes. Treatment with somato...

ea0048o2 | Oral Communications | SFEEU2017

Metastatic pituitary carcinoma in an SDHB mutation positive patient

Tufton Nicola , Roncaroli Federico , Hadjudemetriou Irene , Dang Mary N , Denes Judit , Guasti Leonardo , Thom Maria , Powell Michael , Baldeweg Stephanie E , Fersht Naomi , Korbonits Marta

Case history: A 63-year-old female presented with bi-temporal hemianopia. Pituitary MRI demonstrated a macroadenoma with suprasellar extension. Her medical history included a glomus tumour of the right ear treated with external beam radiotherapy (EBRT) 25 years previously. She had no evidence of pituitary hormone abnormality and had normal urinary metanephrines levels. She underwent transsphenoidal surgery with total resection and full recovery of her visual fields. Immunohist...

ea0035p586 | Endocrine tumours and neoplasia | ECE2014

The anti-proliferative effect of anti-EGFR tyrosine kinase inhibitor in combination with mitotane on H295R adrenocortical cancer cells

Dworakowska Dorota , Dudka Dorota , Weistman Gregory , King Peter , Diaz-Cano Salvador , Korbonits Marta , Grossman Ashley B , Aylwin Simon , Schulte Klaus-Martin , Sworczak Krzysztof , Ng Tony

Introduction: Adrenocortical carcinoma (ACC) is a rare disease with a poor prognosis and limited therapeutic options. Mitotane is considered as a first-line therapy but only 30% of the patients showing an objective tumour response.Erlotinib and gefitinib (tyrosine kinase inhibitors – TKI) inhibit the epidermal growth factor receptor (EGFR), which is highly expressed and occasionally mutated in various cancers. EGFR expression was found to be a good ...

ea0034p425 | Thyroid | SFEBES2014

RET mutation negative familial medullary thyroid carcinoma: four families and literature review

Iacovazzo Donato , Morrison Patrick , Foulkes William , Ross Douglas , Lugli Francesca , Gabrovska Plamena , Lucci-Cordisco Emanuela , Neri Giovanni , Marinis Laura De , Korbonits Marta

Approximately 25% of the reported cases of MTC are familial. Familial MTC can occur as part of MEN2-syndrome or as familial MTC alone (fMTC) defined as more than ten carriers in the kindred, or multiple carriers or affected members over the age of 50 with an adequate medical history excluding pheochromocytoma. The vast majority of MEN2 families (98%), as well as fMTC kindreds (88%) harbour a RET mutation. In MEN2A, mutations at codon-634 (exon-11) account for 85% of all mutati...

ea0070oc7.2 | Endocrine-related Cancer | ECE2020

The role of the tumour microenvironment in pituitary adenoma angiogenesis

Marques Pedro , Barry Sayka , Carlsen Eivind , Collier David , Ronaldson Amy , Awad Sherine , Mendoza Nigel , Muquit Samiul , Dorward Neil , Grieve Joan , Balkwill Frances , Grossman Ashley B , Korbonits Marta

Introduction: Angiogenesis is regulated by different components of the tumour microenvironment (TME) including cytokines and immune cells. Although angiogenesis has been studied in pituitary adenomas (PAs), the role of individual TME components in PA angiogenesis remains largely unknown. We aimed to characterise the role of the TME components in determining the angiogenesis of PAs, focusing on PA-infiltrating immune cells and the PA-derived cytokine network.<p class="abste...

ea0070aep671 | Pituitary and Neuroendocrinology | ECE2020

To score or not to score? Is Ki-67 analysis worthwhile in pituitary neuroendocrine tumours?

Benjamin Loughrey Paul , Craig Stephanie , Herron Brian , Abdullahi Sidi Fatima , McQuaid Stephen , Kelly Paul , Humphries Matt , Parkes Eileen , McArt Darragh , Hunter Steven , Korbonits Marta , James Jacqueline

Pituitary neuroendocrine tumours (PitNETs) are heterogeneous and have limited biomarkers to predict their behaviour, thus making their prognostication difficult. Ki-67 is a protein expressed in active phases of the cell cycle and is one of the biomarkers utilized in routine assessment of PitNET tissue. Current European Society of Endocrinology recommendations advise that histopathological analysis of PitNETs should as a minimum include Ki-67 proliferation index and anterior pi...

ea0031p258 | Pituitary | SFEBES2013

Prevalence of familial isolated pituitary adenomas

Herincs M , Owusu-Antwi S , Chahal H S , Kumar S R , Ozfirat Z , Grossman A B , Druce M R , Akker S A , Drake W M , Korbonits M

While pituitary adenomas (PA) usually occur as a sporadic disease, an increasing number of patients are recognised with a family member also suffering from a PA. If no other syndromic features are present, these families are categorised as FIPA. In published studies, 20% of the FIPA families, 20% of sporadic childhood and 13% of sporadic young-onset (≤30 years) acromegaly patients carry a germline AIP mutation. As familial disease is more aggressive, family scre...

ea0029oc12.3 | Obesity Clinical | ICEECE2012

The Young Investigator Winner

Stadler M. , Toman L. , Storka A. , Wolzt M. , Peric S. , Bieglmayer C. , Wagner O. , Pacini G. , Brath H. , Bech P. , Prager R. , Korbonits M.

Despite the known health hazards of cigarette smoking, many smokers fail to quit smoking, mainly due to nicotine’s addictiveness, but also because of fear from gaining weight. However, the mechanism of weight gain after smoking cessation is not fully elucidated yet.Healthy long-term smokers (28±2 years, 10F/20M, 23.4±1.3 kg/m2) participating in a smoking cessation programme underwent 3-hour oral glucose tolerance tests (oGTT) an...